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Trends
Pseudoenzymes are inactive counter-
parts of classical enzymes and have
evolved in all kingdoms of life, where
they regulate a vast array of biological
processes. The pseudokinases are
one of the best-studied families of
human pseudoenzymes.
Eukaryotic TRIB pseudokinases
evolved from a common ancestor (the
human TRIB2 homolog), and contain a
highly atypical pseudokinase domain
fused to a unique docking site in an
extended C tail that binds to ubiquitin
E3 ligases.
TRIB evolution has led to the appear-
ance of three mammalian TRIB pseu-
dokinases, termed TRIB1, TRIB2, and
TRIB3, which contain both unique and
shared features.
In cells, TRIB pseudokinases act as
modulators of substrate ubiquitination
and as molecular scaffolds for the
assembly and regulation of signaling
modules, including the C/EBP/ tran-
scription factor and AKT and ERK
networks.
TRIB1 and TRIB2 have potent onco-
genic activities in vertebrate cells, and
recent evidence also suggests that
TRIB2 acts as a tumour suppressor,
consistent with the requirement for
balanced TRIB signaling in the regula-
tion of transcription, differentiation,
proliferation, and apoptosis.Review
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The Tribbles (TRIB) pseudokinases control multiple aspects of eukaryotic cell
biology and evolved unique features distinguishing them from all other protein
kinases. The atypical pseudokinase domain retains a regulated binding platform
for substrates, which are ubiquitinated by context-speciﬁc E3 ligases. This
plastic conﬁguration has also been exploited as a scaffold to support the
modulation of canonical MAPK and AKT modules. In this review, we discuss
the evolution of TRIBs and their roles in vertebrate cell biology. TRIB2 is the most
ancestral member of the family, whereas the emergence of TRIB3 homologs in
mammals supports additional biological roles, many of which are currently
being dissected. Given their pleiotropic role in diseases, the unusual TRIB
pseudokinase conformation provides a highly attractive opportunity for drug
design.
Introduction and Historical Perspective
Protein kinases and phosphorylation modulate all aspects of eukaryotic cell biology and,
together with members of the Ubiquitin system, have become highly signiﬁcant for mechanistic
drug targeting [1]. Post-translational modiﬁcation of proteins permits regulatory ﬂexibility and
endows them with the ability to control signaling networks through combinatorial mechanisms.
Consistently, crosstalk between phosphorylation and ubiquitination is thought to be widespread
in eukaryotic signaling [2]. The three TRIB pseudokinases (TRIB1, TRIB2, and TRIB3) represent
a prominent subbranch of eukaryotic pseudoenzymes that are unique within the human kinome
[3,4]. TRIB proteins regulate intracellular cell signaling and appear to have evolved two major
mechanisms of action. The ﬁrst exploits conserved adaptions in the ancient eukaryotic protein
kinase (ePK) fold to position protein ‘substrates’ and control their E3 ligase-dependent ubiq-
uitination, likely through a switch-like pseudokinase mechanism. The second involves a more
obscure scaffolding function, which operates to integrate and modulate signals ﬂowing into and
through canonical MAPK and AKT modules (Figure 1). Accordingly, TRIBs are fundamental
regulators of cell cycle, differentiation, metabolism, proliferation, and cell stress, as reﬂected by
the appearance of several excellent reviews in these speciﬁc areas [5–9].
TRIB pseudokinases represent a subbranch of the CAMK subfamily in the human kinome [3]
and, although a shared eukaryotic evolutionary origin is apparent from bioinformatic compar-
isons [10–12], the molecular basis for their speciﬁc evolutionary trajectory and associated cellular
functions has not been evaluated in depth. Indeed, several critical questions in the TRIB ﬁeld
remain (see Outstanding Questions). For example, it is important to uncover clues as to why284 Trends in Cell Biology, April 2017, Vol. 27, No. 4 http://dx.doi.org/10.1016/j.tcb.2016.11.002
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Figure 1. Classical Tribbles (TRIB) Signaling Features. All TRIB polypeptides contain a variable N-terminal ‘PEST’
domain, a pseudokinase domain lacking a canonical ‘DFG’ (metal-binding) motif, and a unique C-tail, which contains two
key regulatory elements. The HPW[F/L] motif at the beginning of the pseudokinase C-tail targets MAPKK/MEK family
members, giving TRIBs the potential to regulate and/or integrate distinct stress and proliferative MAPK modules. The
conserved structural C-terminal DQXVP[D/E] peptide motif supports a direct association with E3 ubiquitin ligases, including
COP1, which speciﬁes K48-linked ubiquitin chains in substrates such as C/EBP/, thereby regulating transcription factor
stability via the ubiquitin proteasome system. TRIBs can also modulate AKT/FOXO signaling modules, although the
molecular details for individual pseudokinases remain to be clariﬁed. Overall, a series of shared mechanisms contribute
to TRIB-regulated signaling pathways that support cell context-speciﬁc programs of cellular differentiation, proliferation, and
survival. Abbreviations: P, phosphate; Ub, ubiquitin.three distinct TRIB pseudokinase polypeptides evolved in human cells and how they mecha-
nistically support diverse regulatory and disease-associated signaling pathways (Figure 1). An
analysis of these issues represents a central focus of this review.
Origin and Evolution of Tribbles Pseudokinases
In mammalian cells, the three related TRIB family members (TRIB1–3) are classed as serine/
threonine pseudokinases that either lack (TRIB1), or have low, (TRIB2 and TRIB3) vestigial ATP
afﬁnity and phosphotransferase capacity when analyzed in vitro [10,13,14]. In many cells, TRIB1
and 2 pseudokinases are rather unstable cellular proteins, likely due to conserved destabilizing
motifs present in the small N-terminal PEST region [15,16]. The adjacent TRIB pseudokinase
domain is linked to a short C-terminal ubiquitin E3 ligase-targeting motif, which was recently
proposed to interact in cis with the TRIB regulatory pseudokinase domain [14,17]. In addition, the
pseudokinase domain has evolved structurally [18] to correctly position and regulate potential
substrates for ubiquitylation by a variety of classes of Ubiquitin E3 ligases [19]. The formation of
regulated multiprotein complexes that then dictate cellular signaling is a recurring theme in TRIBTrends in Cell Biology, April 2017, Vol. 27, No. 4 285
biology (Figure 1). However, while the roles of TRIB pseudokinases in cellular signaling, metabo-
lism, and disease are increasingly appreciated, little is known about their early origins and the
speciﬁc signaling requirements that have shaped them during evolutionary history.
TRIB proteins derive their name from the single metazoan ﬂy gene ‘Tribbles’ (Trbl), which
encodes a pseudokinase with developmental roles in this model genetic organism. Trbl was
discovered through three independent Drosophila screens, which revealed genes and muta-
tions that affect either oogenesis via Slbo, the alpha ortholog of the mammalian CCAAT
enhancer-binding protein (C/EBP/) transcription factor [20] or gastrulation during embryogen-
esis via String, the ﬂy ortholog of the CDC25 phosphatases [21,22]. Of major interest, Trbl
mutant cells exhibit premature mitosis, leading to defective gastrulation based on an inability to
degrade target proteins in a timely fashion. Trbl ﬂy models continue to be instrumental in
revealing requirements for the pseudokinase domain in biological signaling events that have
been conserved in vertebrate eukaryotes [23,24]. For example, String is the Drosophila ortholog
of the CDC25 dual-speciﬁcity phosphatases, which initiate eukaryotic S-phase and mitosis and
are themselves regulated at various cell cycle checkpoints. Recent data conﬁrmed that TRIB2
protein expression is also cell cycle regulated in human cells, positioning it as a potential
modulator of CDC25 phosphatases, which it degrades through a ubiquitin- and protea-
some-dependent mechanism [25]. Fly Trbl was also reported as an interacting partner for
the proto-oncogene AKT, and this interaction also appears to be conserved among the
metazoa, where TRIB3 binding directly modulates mTORC2-dependent AKT activation [26–
29], seemingly without affecting AKT stability. TRIB2 has also been described as a dosage-
dependent suppressor of the AKT-phosphosubstrate FOXO, speciﬁcally as a modulator of the
cytoplasmic localization of FOXO3a in human cells [30]. Interestingly, a TRIB3-regulated AKT-
FOXO transcriptional network also operates in human neurons [27], where TRIB3 expression
levels are inversely correlated with the Parkinson's disease-associated ubiquitin E3 ligase
PARKIN [31]. Indeed, TRIB3, but not TRIB1 or TRIB2, mRNA expression is upregulated in
the developing murine brain [32] and TRIB3 immunostaining is markedly increased in sections of
substantia nigra from Parkinson's disease brains [31]. The relatively mild cognitive and memory
brain phenotypes observed in a C57BL/6 TRIB3-deﬁcient mouse model [31] support the notion
that normalizing pathological increases in TRIB3 levels in neurodegenerative disease might be an
interesting new medical strategy.
To address major knowledge gaps in how the functional specialization of TRIB genes occurred
during evolution, we identiﬁed and classiﬁed TRIB-related sequences from all the major taxo-
nomic groups where they are present (Figure 2). Taxonomic analysis of these sequences
demonstrates that they are almost entirely conﬁned to the animal kingdom, and are absent
in non-metazoan eukaryote kinomes, including those annotated in fungi, plants, and choano-
ﬂagellates. We speculate that this represents a shift towards ubiquitination-based substrate
regulation by the TRIB pseudokinase domains in metazoan eukaryotes, although other explan-
ations are possible. As shown in Figure 2, the statistically derived TRIB2 signature sequence is
the earliest (most ancestral) member among the TRIB1, 2, and 3 family. Consistently, orthologs
of TRIB2 (but not TRIB1 or TRIB3) can readily be detected in the oldest metazoans, such as
cnidarians (Nematostella vectensis) and sponges (Amphimedon queenslandica), whereas
TRIB1 and TRIB3 orthologs are restricted to speciﬁc later metazoan lineages that led to the
vertebrates, where all three TRIBs pseudokinases are consistently preserved. It is likely that the
emergence of TRIB1 and TRIB3 at later stages of evolution was driven by unique regulatory
requirements associated with signaling integration by these proteins in higher organisms. TRIB1
likely appeared through TRIB2 gene duplication during the diversiﬁcation of vertebrates from
invertebrates, since multiple copies of TRIB2 and a single copy of TRIB1 are observed in non-
mammalian chordates, such as ﬁsh (Actinopterygii) and reptiles. Remarkably, the TRIB3-speciﬁc
sequence signature appears in all mammalian lineages, and from the extensive data analyzed286 Trends in Cell Biology, April 2017, Vol. 27, No. 4
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Figure 2. Taxonomic Coverage and Analysis of Tribbles (TRIB) Family Kinases. The number of TRIB1, TRIB2, and
TRIB3 orthologs detected across all the major metazoan species for which accurate genomic kinome data are available are
shown. Each row represents a single species and the number of TRIB orthologs identiﬁed in each species is indicated.
Orthologs were identiﬁed by scanning a hierarchical sequence proﬁle of diverse ePKs and TRIB family members against
sequenced proteomes contained in the latest nonredundant proteome sequence set in Uniprot (downloaded October
2016) using the MAPGAPS program [93]. The most signiﬁcant hits to TRIB1, TRIB2, and TRIB3 proﬁles were annotated as
putative orthologs. Fragmentary sequences of less than 150 amino acids in length were ﬁltered out. Reptilian TRIB3
orthologs were detected in larger sequence databases (NCBI nr, EST) and all three TRIB pseudokinases are observed in
reptilian species (including alligator) in the corresponding Uniprot proteome sequence set.here, emerged relatively recently during the diversiﬁcation of mammals from non-mammalian
chordates (Figure 2). While most mammalian species harbor at least one copy of TRIB1, 2, and
3, some encode multiple copies, suggesting functionally relevant gene duplications; an extreme
version being the marmoset Callithrix jacchus, whose genome encodes three copies of TRIB1,
one copy of TRIB2, and 2 copies of TRIB3. The cellular consequences of these duplications are
obscure, although we speculate that they represent a requirement for new biological functions
associated with higher vertebrates, perhaps including unique TRIB3 roles in highly evolved
brains, which might be driven by increased gene dosages of this speciﬁc pseudokinase.
Whatever their speciﬁc functions, TRIB genes have likely been coopted into evolutionarily
appropriate biological roles that depend on their unique pseudokinase properties compared
with catalytically active kinases (Box 1), which have been deﬁned previously [3,10,13,33–36].
What Deﬁnes A Tribbles Pseudokinase?
TRIB pseudokinases are predicted to be three-domain proteins containing an N-terminal
PEST region, a pseudokinase domain (containing an unusual N-lobe and a canonical C-lobe)Trends in Cell Biology, April 2017, Vol. 27, No. 4 287
Box 1. CAMK Subfamily Sequence Alignment within the (Pseudo)Kinase Domain
Figure I shows an Alignment and Sequence Logo amino acid conservation plot of Drosophila TRIB (Trbl), human TRIB1–3, human CASK (a CAMK-related
pseudokinase), canonical human CAMK1/, CAMK2g, and the benchmark PKAcb AGC kinase domains. A comparison of sequences around the degraded TRIB
glycine-rich loop, the conserved b3 lysine, the unusual TRIB catalytic loop, and the metal-binding ‘DFG’ motif (including the TRIB-speciﬁc E[S/N]LED sequence) are
boxed in red. Conserved amino acid motifs at these positions together deﬁne the TRIB pseudokinase domain signature (applied in Figures 2 and 3, main text). The
HPW[F/L] MEK binding site at the junction of the TRIB pseudokinase C-lobe and C-tail is boxed in blue. Numbering refers to amino acid boundaries within each human
(pseudo)kinase domain.
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Figure I. CAMK Subfamily Sequence Alignment of selected (Pseudo)Kinase Domains.and a C-terminal COP1-binding peptide region, which interacts in cis with a pocket formed
adjacent to the unusual /C-helix found in the TRIB pseudokinase domain (Figure 1). Recent
structural analysis of the human TRIB1 pseudokinase domain [14] conﬁrms an atypical kinase
fold that diverges most notably in the N-lobe, which harbors most of the catalytic machinery, but
which preserves a putative substrate-binding site in the C-lobe of the kinase domain. No
structural information has been reported for the N-terminal PEST domain, or for any domains
of the TRIB2 or TRIB3 pseudokinases. Although these same deﬁning regions are conserved
across TRIB polypeptides when comparing the pseudokinase domain with catalytically active
CAMK relatives (Box 1), the availability of tens of thousands of protein kinase-like sequences
from diverse organisms provides a timely opportunity to deﬁne distinguishing or unique
features of TRIB pseudokinases using statistical comparisons of large data sets. Such
approaches across kinomes have previously been invaluable to provide new insights into
protein kinase structure, function, and evolution [37–42]. As collated in Figure 3, a Bayesian
statistical comparison reveals strong selective constraints imposed on each of the individual
TRIB kinase sequences during evolution. At a gross level, these constraints correspond to
‘TRIB-speciﬁc’ residues and/or motifs that are highly conserved in TRIB kinases but strikingly
different in the closely related pseudokinase SgK495 and the broader family of canonical288 Trends in Cell Biology, April 2017, Vol. 27, No. 4
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Figure 3. Distinguishing Sequence and Structural Features of Tribbles (TRIB) Pseudokinases. (A) Constraints that help distinguish TRIB kinases from all other
kinases are shown in a contrast hierarchical alignment, where representative TRIB kinases from diverse organisms constitute the display alignment; all TRIB-like
sequences available (492 sequences, September 2016) constitute the foreground alignment, and related CAMK sequences (79 487 sequences) constitute the
background alignment. Complete foreground and background alignments are not shown due to the hundreds of text pages required. Instead, information encoded in
these large alignments is shown as residue frequencies directly below the display alignment where, for example, the number ‘50 indicates that the corresponding residue
occurs 50–60% of the time at the corresponding position. The histogram above the alignment plots the strength of the selective pressure shifting residues at each position
in the TRIB kinases away from the residue composition observed at the corresponding positions in CAMKs. Residue positions subject to the strongest constraints are
highlighted with chemically similar amino acids colored similarly; weakly conserved positions and nonconserved positions are shown in dark and light gray, respectively.
Dots below the histograms indicate those residue positions that most strikingly distinguish TRIB kinases from CAMKs as selected by the Bayesian pattern partitioning
procedure [94]. Key secondary structural elements are indicated above the alignment; amino acid numbering corresponds to human TRIB2. Identiﬁers for TRIB
sequences used in the display alignment can be compared with canonical kinase sequences by inspecting Box 1. (B,C) Modeling of the structural disposition of TRIB-
speciﬁc residues forming the regulatory activation loop, atypical DFG motif (E[S/N]LED), and /C helix in human TRIB2. The kinked /C-helix is shown in yellow and
the activation loop (A-loop) is shown in magenta. TRIB family conserved residues are shown in green. Putative hydrogen-bonding interactions in the modeled structure
are shown by broken lines and the putative substrate-binding site in the C-lobe is labeled. Structural image was generated using PyMoL. Speciﬁc TRIB gene identiﬁers are
listed in the legend to Figure 4.CAMKs. We focus on the most distinctive features in the core (conserved) regions of the TRIB
family, namely the pseudokinase domain (Figure 3A) and ﬂanking C-terminal tail (Figure 4A). In
passing, we note that the N-terminal PEST domain contains distinct sequence motifs that are
characteristic of each TRIB variant, and these subfamily speciﬁc motifs are assumed to regulate
distinct protein turnover patterns in both ‘normal’ and disease-associated cells [43,44].
Within the pseudokinase domain, TRIB-speciﬁc constraints are imposed on residues and/or
motifs that are dispersed in primary sequence, but that spatially cluster in two critical regions of
the pseudokinase domain (Figure 3A), namely the active site and C-terminal substrate-binding
lobe. The divergent nature of active site residues in TRIB pseudokinases has been noted in
previous studies and in the recently solved crystal structure of TRIB1 [14], where these residues
mediate speciﬁc hydrogen bonding and van der Waals interactions (Figure 3B) that stabilize the
activation loop in a unique inactive conformation that serves to preclude nucleotide binding in theTrends in Cell Biology, April 2017, Vol. 27, No. 4 289
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Figure 4. The C-tail, A Unique ‘Degrading’ Feature of Tribbles (TRIB) Pseudokinase Polypeptides. (A) Alignment of TRIB pseudokinase C-tail segment
highlighting key conserved residues and motifs found in eukaryotic TRIB pseudokinases. See Figure 2 legends for details. Unique TRIB gene identiﬁers are: Trib1 Human
Q96RU8; Trib1 Mouse Q8K4K4; Trib1 Cow A6QLF4; Trib1 Elephant G3T9X9; Trib1 Chicken H9L0P6; Trib1 Green anole G1KJZ8; Trib1 Alligator A0A151P7Z3; Trib1
Frog F7BWB1; Trib1 Coelacanth H3ALB4; Trib1 Zebraﬁsh E7FD70; Trib2 Human Q92519; Trib2 Mouse Q8K4K3; Trib2 Cow Q5GLH2; Trib2 Elephant G3TC04; Trib2
Chicken Q7ZZY2; Trib2 Green anole G1K8G5; Trib2 Alligator A0A151N8V7; Trib2 Frog Q76D08; Trib2 Coelacanth H3A37; Trib2 Zebraﬁsh E7F3S2; Trib2 Fire ant
XP_011171156.1; Trib2 Acorn Worm XP_002742313.1; Trib2 Threadworm A0A0K0E067; Trib2 Sea hare XP_005101496.1; Trib2 Sea urchin XP_792075.2; Trib2
Sponge I1G1T0; Trib3 Human Q96RU7; Trib3 Mouse Q8K4K2; Trib3 Cow Q0VCE3; Trib3 Elephant G3SZ76; Trib3 Alligator A0A151NVV1. (B) Common mechanism for
structural tethering of the C-tail to the kinase domain in TRIB2 (model based on TRIB1 X-ray analysis, Protein Data Ban ID: 5CEM) and two canonical kinase families, with
PKA representing the AGC kinases [39] and ERK2 representing the MAP kinases [95]. All three subfamilies of (pseudo)kinase are regulated by conformational changes in
the C-terminal tail that directly engage the kinase domain in cis.TRIB1 ATP-binding site [14]. In contrast to the pseudoactive site, TRIB-speciﬁc divergence in
the C-lobe has not been evaluated in depth, despite the overall structural similarity of TRIB1 to
the C-lobe of canonical CAMKs. Some of the TRIB-speciﬁc residues of unknown functions in the
C-lobe include the D[KR]H[GA]C motif in the activation loop, H138 in the D-helix, and a
conserved cysteine residue in the /H helix (Figure 3B,C). In the crystal structure of TRIB1,
the region corresponding to the D[KR]H[GA]C motif in the activation segment is disordered.
However, modeling of the activation loop in both an active and inactive conformation suggests
that TRIB-speciﬁc residues in the C-lobe potentially stabilize the activation loop in an auto-
inhibitory conformation that might occlude substrate binding, as previously revealed by struc-
tural analysis of TRIB1 [14]. The C-lobe is a universal docking site for protein substrates
in canonical kinases and autoinhibitory conformations involving the activation loop have
been observed in multiple kinases, including canonical CAMKs [45]. Thus, it is likely that a
near-universal regulatory kinase mechanism is also at play in the TRIB pseudokinases, and that
TRIB-speciﬁc constraints in the pseudokinase domain reﬂect speciﬁc variations on a common
mechanistic autoregulatory theme found in most, if not all, kinases.
A Unique C-Terminal Regulatory Region in TRIB Pseudokinases
In addition to characteristic residues and/or motifs in the pseudokinase domain, the critical
C-terminal tail involved in protein–protein interactions is readily identiﬁed as a distinguishing
feature of TRIB kinases; this segment is highly conserved in TRIB kinases, but strikingly different
in kinases outside of the TRIB subfamily (Figure 4A). No detectable similarity is observed at this290 Trends in Cell Biology, April 2017, Vol. 27, No. 4
locus between TRIB primary sequences and any other evolutionarily related protein kinases,
deﬁning the tail as a statistically unique feature. The TRIB C-terminal tail is deﬁned by two unique
sequences: the HPW[F/L] and DQXVP[D/E] motifs near the extreme N and C-terminal regions of
the C-tail, respectively (Figure 4A). The HPW[F/L] motif is involved in binding of MEK1 (and other
MAPKK dual-speciﬁcity kinases) to TRIB pseudokinases [46–48], whereas the DQXVP[D/E]
motif is intimately involved in COP1 binding in all TRIB proteins [49,50] and required to drive
tumorigenesis in leukemia models [51]. Although these motifs are not observed in the C-terminal
tail of other protein kinases, they are predicted to engage with the TRIB pseudokinase domains
in a manner analogous to canonical, well-studied protein kinases, such as PKA and MAP
kinases, which utilize these ﬂanking regions to drive regulatory mechanisms involved in kinase
activation and substrate phosphorylation (Figure 4B). This common regulatory theme, evident
between a divergent pseudokinase family (modeled as TRIB2) and multiple canonical kinase
families in which allosteric coupling is established (represented by AGC kinases and MAP
kinases), reinforces how ﬂanking sequences outside the (pseudo)kinase domain appear to
have been repeatedly used to permit switch-like regulation of the kinase fold. Of particular
interest for the TRIBs, this mechanism is predicted to be independent of catalysis, although the
phosphorylation of a highly speciﬁc localized cellular substrate is challenging to rule out
completely.
Interestingly, the HPW[FL] motif is tethered to the C-lobe of the pseudokinase domain in the
recently solved TRIB1 crystal structure, while the DQXVP[D/E] motif is tethered to the N-lobe.
Why would such tethering of the C-tail to the pseudokinase domain be important for TRIB
functions? One possibility is that this interaction allows efﬁcient coupling of COP1 binding (or
other regulatory binding proteins) in the C-tail with coopted substrate-binding functions associ-
ated with the degenerate pseudokinase domain. Such a view may also explain why the C-helix
and activation loop conformation in the TRIB1 (and presumably TRIB2 and TRIB3) pseudoki-
nase domain are stabilized in a unique conformation [14], since potential conformational
changes in these regions can be allosterically coupled to the COP1-binding site, which is
absolutely required for substrate ubiquitination. Indeed, the binding of a TRIB1 C-tail-derived
peptide sequence to a COP1-motif peptide is of a measurably higher afﬁnity when compared
side-by-side with a TRIB1 protein containing the C-tail [18], the latter retaining coupled pseu-
dokinase and C-tail interactions. Thus, protein allostery, rather than phosphorylation-based
catalysis more commonly associated with canonical protein kinases, might be the key driving
force for TRIB kinase evolution and functional specialization. In turn, this suggests that TRIBs
evolved to be pseudokinases that exploit a noncanonical (but still bilobal) protein kinase fold
that modulates cellular ubiquitination through protein–protein interactions. The reuse of a
pseudokinase domain to mediate signaling has also been noted in other evolutionarily distinct
pseudoenzymes, including the PAN3 and ADCK3 pseudokinases, which have reﬁned the kinase
fold to scaffold enzyme-catalyzed processes as diverse as mRNA deadenylation [52] and
Coenzyme Q biosynthesis [53]. In support of a coevolutionary hypothesis in TRIB pseudoki-
nases, it is interesting to note that some TRIB2 orthologs (such as a pathogenic thread worm)
lack detectable sequence similarity in the C-tail sequence, and also diverge in complementary
C-tail docking regions in the pseudokinase N-lobe (modeled as deletions in alignment Figures 3A
and 4A). Since parasitic threadworms kinomes are currently poorly annotated, we cannot rule
out that these sequences either exist or have become cryptic at the amino acid level. Nonethe-
less, we suspect that characterizing unusual TRIB variants and potential mechanisms of action in
a variety of model organisms will be important for fully understanding TRIB functions in both
normal human biology and disease.
Tribbles Links to Cancer: A Corruption of Cell Signaling?
In humans, the TRIB gene family has been implicated in many different cancers, but especially in
melanoma, lung, liver, and acute leukemias [5,6]. The molecular basis of these disease links isTrends in Cell Biology, April 2017, Vol. 27, No. 4 291
still in the process of being dissected in a variety of cell types and model systems. However, a
major mechanistic function of TRIBs in cancer cells appears to be the (inappropriate) association
of TRIB proteins with substrate degradation and stability networks, leading to a subsequent
imbalance in timely regulation of crucial transcriptional networks. For example, TRIB2-mediated
degradation of the transcription factor C/EBP/ is known to have an oncogenic role in the
development of acute myeloid leukemia (AML) [54,55], lung [56], and liver cancers [57,58]. These
studies all point to abnormal regulation of TRIB transcription, translation, or protein turnover as
disease drivers, and below we use the hematological system and other cancer models to
describe how this is thought to work mechanistically at the cellular level in mammals.
TRIB Pseudokinase Function in Myeloid and Lymphoid Systems
The Trib2 gene was ﬁrst identiﬁed as a murine myeloid oncogene, since its overexpression in a
bone marrow transplant model leads to the development of a potent transplantable AML with
100% penetrance and short latency [54]. In this model, TRIB2 preferentially degrades the p42
isoform of the myeloid transcription factor C/EBP/, which leaves the truncated oncogenic p30
isoform (which lacks the canonical TRIB-binding site identiﬁed in the TRIB1 crystal structure)
intact [54]. TRIB1 (but not TRIB3) functionally resembles TRIB2 in this phenotypic mouse cancer
model, since it also degrades C/EBP/ and causes highly penetrant AML (Figure 5), in line with a
postulated TRIB evolutionary pathway that led linearly between TRIB2 and TRIB1 and, hence, on
to TRIB3 (Figure 2) and the high level (71%) of amino acid similarity between TRIB1 and TRIB2
within the pseudokinase domain. The functional difference between TRIB pseudokinases in
these systems is further highlighted by their differential expression in hemopoietic cells [59], with
TRIB2 highest in the lymphoid cell compartment, TRIB1 highest in the myeloid cell compartment,
and TRIB3 expression constant across all cell types examined. Interestingly, the human TRIB1
gene is located at the same chromosomal locus (8q24.13) as the MYC oncogene and, therefore,
MYC (and potentially TRIB1) cancer susceptibility genes are co-ampliﬁed in a signiﬁcant
percentage of human tumours, where the 8q24 amplicon is the most commonly ampliﬁed
region across multiple cancer types [60]. Furthermore, an ‘oncogenic’ R107L TRIB1 mutation in• Dependent on C/EBPα
• Defecve MAPK signaling
• Defecve cell cycle
TRIB levels
TRIB levels
Oncogenic phenotypes
Tumor-suppressor phenotype
WT BM
+TRIB1 AML, 100% penetrant
AML, 100% penetrant
APL with reduced
sensivity to ATRA
NO AML
Refs
(A)
(B)
[48,71]
[51,54]
[75,76]
[55]
[72]
[73]T-ALL
T-ALL
WT BM
+TRIB2
Cebpa–/– BM
+TRIB2
WT BM
+NOTCH1
Trib2–/– BM
+NOTCH1
PML/RARA+MYC
+TRIB1
Figure 5. Tribbles 1 (TRIB1) and TRIB2 Pro- and Anti-tumorigenic Activities Associated with Vertebrate
Leukemias. (A) Murine cancer models in which TRIB1 and TRIB2 function as oncogenes when TRIB1 or TRIB2 are
overexpressed (+TRIB1, + TRIB2) leading to fully penetrant, fatal acute myeloid (AML, green), but not lymphoid (T cell acute
lymphoblastic; T-ALL) leukemias. Elevated TRIB1 expression also contributes to chemotherapy resistance (a protumori-
genic response) in APL (indicated in a PML/RARA + MYC model). (B) Mouse models in which the loss of TRIB2 reveals a
tumor-suppressive activity. This is shown through homozygous TRIB2 knockout, which results in an accelerated lymphoid
(T-ALL induced by active NOTCH1, red), but not myeloid, leukemia. Abbreviations: ATRA, all-trans-retinoic-acid, an APL
therapy; APL, acute promyelocytic leukemia (a subtype of AML); BM, bone marrow; Cebpa–/–, C/EBP/-knockout mouse;
Trib2–/–, Trib2-knockout mouse; WT, wildtype mouse. Citations refer to in vivo mouse models of leukemia demonstrating
oncogenic or tumor-suppressive TRIB biology.
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the pseudokinase domain has been identiﬁed in a Down syndrome-related AML [7]; this Arg
residue is broadly conserved across the TRIB pseudokinases (Figure 3A, asterisk), but is a
Leu residue in the canonical kinase PKA, where it packs up against hydrophobic residues in the
C-terminal tail [39]. Interestingly, when this amino acid was analyzed across the kinome [61], an
Arg or Lys residue was found in approximately 35% of human kinases, with Leu representing the
most common single amino acid, accounting for approximately 25% of (pseudo)kinases in the
human ePK family. Although mechanistic effects of an R107L substitution are not fully under-
stood in TRIB1, enhancement of both ERK phosphorylation and C/EBP/ degradation have
been demonstrated in an R107L TRIB1 murine bone marrow model of AML [62]. Based on the
crystal structures of PKA and TRIB1, we speculate that this mutation contributes to abnormal
TRIB1 pseudokinase function by disrupting regulatory protein interactions with interacting
partners, such as MAPKK family members [46], Ubiquitin E3 ligases, or cis-acting ﬂanking
regulatory segments in TRIB itself. Of related interest, TRIB1 gene polymorphisms are also
associated with nonalcoholic liver and metabolic syndromes [63], consistent with a relatively
specialized function for TRIB1 in lipid metabolism [8,43].
In the hematopoietic system, C/EBP/ is essential for granulopoiesis [64] and TRIB1 and TRIB2-
mediated degradation of C/EBP/ p42 blocks this differentiation process. Mechanistically,
degradation of C/EBP/ p42 by TRIB2 is known to occur via a proteasome-dependent pathway
involving lysine 48 polyubiquitination [55]. Using mouse genetics, it was shown that the presence
of C/EBP/ is paradoxically required for TRIB2-induced AML, and only in the presence of the
C/EBP/ p42 isoform is a cooperative effect observed with TRIB2 and C/EBP/ p30 [55].
Structure–function analysis of TRIB2 revealed that deletion or mutation of the TRIB signature
C-terminal E3 ligase COP1-binding site (Figure 4A) prevented TRIB2-mediated degradation of
C/EBP/ and this correlated directly with a failure to induce AML in vivo [51]. Interestingly, TRIB1,
2, and 3 all retain COP1-binding motifs in their C-tails (Figure 4A), but TRIB3 alone fails to drive
C/EBP/ degradation. This ﬁnding is consistent with a unique (or only partially overlapping) set of
target substrates for TRIB3 in comparison to TRIB1 and TRIB2. However, preserved function-
ality in the C-tail in TRIB3 is conﬁrmed by its ability to facilitate cellular COP1-mediated
ubiquitination and degradation of Acetyl CoA carboxylase, the rate-limiting enzyme in fatty acid
synthesis [50]. Distinct ubiquitin E3 ligases have also been associated with TRIB2 signaling,
including TRIM21 in a lung cancer model [56]. In liver cancer models, TRIB2 overexpression
conversely stabilizes the co-activator YAP, an oncogenic transcription factor, via binding to the
distinct E3 ubiquitin ligase b-TRCP [57,58]. Intriguingly, and in contrast to COP1 and TRIM21,
TRIB2 interaction with b-TRCP leads to the inhibition instead of promotion of substrate
degradation; it remains unclear whether post-translational modiﬁcations control the targeted
interaction of different TRIB pseudokinases with speciﬁc ubiquitin ligases. However, in terms of
feedback regulation, TRIB2 stability has also been shown to be regulated at the protein level in
liver cancer cells, in part due to the downregulation of the E3 ligase SMURF1 [16].
Through their interaction with ubiquitylated transcription factors, or regulation of signaling
pathways that culminate in cell type-speciﬁc reprogramming, TRIB pseudokinases are regulated
by, and fundamental regulators of, gene transcription networks. An analysis of TRIB1, 2, and 3
promoters conﬁrms that TRIB1 and 2 both have putative E2F and C/EBP/ transcription factor-
binding sites among a large number of conserved canonical transcription factor sequence
determinants (Box 2). Consistently, TRIB2 has been shown to be part of a regulatory loop
involving E2F1 and TRIB2, in which E2F1 binds to the TRIB2 gene promoter to drive expression
of the TRIB2 protein, which is then positively reinforced via p30 C/EBP/ expression of E2F1
[65]. In T cell leukemia models, the Paired homeobox transcription factor PITX1 was shown to
regulate TRIB2 [66]. In addition, aberrant TAL-1 activation, which is detected in up to 60% of T
cell acute lymphoblastic leukemias (T-ALLs) [67], was shown to transcriptionally target TRIB2
[68], allowing TRIB2 to positively reinforce an oncogenic transcriptional program involvingTrends in Cell Biology, April 2017, Vol. 27, No. 4 293
Box 2. Predicted Transcription Factor-Binding Sites in Human and Murine TRIB Gene Promoter Regions
Transcription factor-binding sites were predicted using Transcription Element Search System (TESS) software [96], based
on the sequence of the extended 50 untranslated regions (UTR) sequenced from human and murine TRIB1 (Figure IA), TRIB2
(Figure IB), or TRIB3 (Figure IC) genetic loci. Twelve canonical transcription factor-binding sites identiﬁed in the two sets of
promoters are colored according to the key. Note that several functional E2F1 and C/EBP/-binding sites on the TRIB2
promoter predicted in this analysis have been experimentally veriﬁed [65]. The differences in length of the 50UTR region of
each promoter analyzed are indicated for reference. Note the relatively large predicted number of transcription factor-binding
sites for TRIB2 compared with the relatively small number of predicted transcription factor binding sites for TRIB3.
(A)
Key:
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c-Myc/c-Myb
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E2F
Egr1
ETA/F
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NF-1
NF-E
PPARα
PU-1
WT1
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Human Trib2 gene 5′ UTR
Murine Trib1 gene 5′ UTR
Murine Trib2 gene 5′ UTR
Human Trib3 gene 5′ UTR
Murine Trib3 gene 5′ UTR
(B)
(C)
Figure I. Transcription Factor-Binding Sites in vertebrate TRIB Gene Promoters.
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GATA3, RUNX1, MYB, and E2A, potentially balancing the oncogenic and tumor-suppressive
biological activities of these factors [69].
Despite being capable of driving myeloid leukemia when overexpressed alone, it is assumed
that cooperating lesions occur in TRIB1 and TRIB2 mouse leukemia models (Figure 5).
Putative cooperating genes in TRIB1 and TRIB2-mediated AML include HOX pathway genes,
such as HOXA9, MEIS1, NUP98-HOXD13, and C/EBPAp30 [48,55,70,71]. Gene expression
analysis has revealed that TRIB2 expression levels, while generally low in AML, are higher in
PML-RARA-positive leukemia than in PML-RARA-negative leukemia [59]. As described, the
TRIB1 gene is located on chromosome 8, the most common chromosomal gain in human
AML and APL (distinguished by the fusion oncogene PML/RARA). The hypothesis that TRIB1
and PML/RARA cooperate has been tested and, while they do not cooperate to drive a
shorter latency leukemia in vivo, TRIB1 and PML/RARA have functionally redundant inhibitory
effects on C/EBP/, which also impacts responses [72] to therapeutic All-Trans Retinoic Acid
(ATRA, Figure 5).
The association of TRIB2 with a subset of AMLs with dysregulated C/EBP/ is especially
intriguing, since T lymphoid genes, including NOTCH1 [73] and CD7, as well as CD34, a stem
cell gene, also associate with this subset [74]. It is interesting to speculate that TRIBs may have a
role in lineage decisions or phenotypic characteristics of myeloid and lymphoid leukemias, which
may be determined by their speciﬁc cellular substrates. While it was shown that TRIB2 is a
transcriptional target of the T cell transcription factor NOTCH1 [74], the absence of TRIB2 in a
murine TRIB2-knockout model [75] was found to accelerate NOTCH1-driven T-ALL (Figure 5).
This work also revealed a novel tumor suppressor-like function for TRIB2 in the cell cycle and
proliferation of early T cell progenitor cells, and associated high levels of TRIB2 expression with
early immature T-ALL and deregulated MAPK signaling [75]. TRIB2 is cyclically expressed during
the cell cycle and has the ability to promote the proteasomal degradation of the mitotic regulator
CDC25C, which might explain some of the uncontrolled proliferation characteristics of leukemia
[25]. It was subsequently conﬁrmed in an independent study that this tumor-suppressor activity
of TRIB2 is lymphoid cell speciﬁc [76].
TRIB Pseudokinase Functions in other Model Cancer Systems
Further evidence for TRIB2 as a modulator of tumorigenic activity comes from liver cancer
cells, where the overexpression of TRIB2 was shown to negatively regulate WNT signaling
activity, leading to inhibition of cell growth [19]. The cell models in this study have wildtype
(WT) b-catenin, and the authors conﬁrmed that TRIB2 overexpression reduced WNT-
mediated transcriptional activity and decreased levels of b-catenin and TCF4 protein.
Consistent with this model, the loss of TRIB2-impaired liver cancer cell survival in vitro
and in vivo [57] is associated with a dominant b-catenin mutation. Interestingly, the broad
analysis of all cancers failed to identify conserved mutations or chromosomal alterations
involving TRIB2. By contrast, its elevated expression is strongly associated with cancer
prognostics [77]. Indeed, TRIB2 has been identiﬁed as a candidate biomarker for melanoma
diagnosis and progression, because it exhibits low expression in healthy skin samples,
increases in benign melanoma, with the highest expression seen in malignant melanoma
samples [78]. In addition, TRIB1 expression has been shown to be essential for the survival of
prostate cancer cells and is linked with an aggressive disease phenotype and poor prognosis
[79]. TRIB1 is also involved in the etiology of glioma [80], breast [81], ovarian [82], and
follicular thyroid cancer [83]. TRIB3 expression was found elevated in patients with colorectal
cancer and its expression correlated with poor overall survival [84]. TRIB3 gene expression, in
contrast to TRIB3 protein expression [85], has been shown to correlate with poor prognosis
in patients with breast cancer [86] and a poor prognosis in patients with non-small cell lung
cancer (NSCLC) [87].Trends in Cell Biology, April 2017, Vol. 27, No. 4 295
Outstanding Questions
What is the structural basis for the dis-
tinct cellular roles of TRIB pseudoki-
nases? In particular, how do subtle
variations in sequence identiﬁed in
the three distinct, but related, pseudo-
kinase domains drive cell signaling?
Will a combination of X-ray and NMR
approaches be needed to evaluate
TRIB dynamics in the complete poly-
peptide in comparison to the isolated
pseudokinase domain?
What are the speciﬁc binding partners of
the three TRIB pseudokinase polypep-
tides, within and across the PEST
region, the pseudokinase domain and
the C-tail? Can these regions be
trapped with substrates bound and
studied by mass spectrometry, and
are all substrates that bind actively ubiq-
uitinated? Furthermore, is this process
controlled on the pseudokinase, or in a
processive manner after release? Finally,
how many different ubiquitin E3 ligases
do the TRIB pseudokinases engage?
What is the role (if any) of the vestigial
ATP binding detected in human TRIB2
and TRIB3 in vitro? This is an important
question, since the concentration of
ATP in cells is in the mM range, which
might be sufﬁcient for TRIB pseudoki-
nases to have nucleotide-dependent
mechanisms, as appears to be the
case for several other pseudokinases.
In this context, do TRIB pseudokinasesConcluding Remarks
The appearance and retention of pseudoenzymes during evolution in essentially all enzyme
families suggests that these domains are malleable templates that can be coopted for new
biological functions when required [88–90]. This is clearly demonstrated within the human
protein kinase superfamily by the three TRIB pseudokinases, which together control large
networks of cellular signaling pathways, many of which are known to be dysregulated in disease.
In this review, we have highlighted the importance of classifying and analyzing each TRIB family
member as a unique pseudokinase variant, and this is most clearly shown by comparing their
evolutionary and disease-associated biology in vertebrates. The evolution of TRIB1 and TRIB3
from a common TRIB2 ancestor is particularly interesting and, by using unique structural and
mechanistic features, TRIB pseudokinases appear to have evolved a set of fundamental
biological roles, some of which are shared, at least in the simplistic experimental cell and animal
models evaluated thus far. In the future, proteomic and cell biology approaches will permit the
accurate dissection of the common and speciﬁc TRIB machinery that brings about the three
TRIB pseudokinase signaling modules. The mechanisms that underlie the ability of TRIB proteins
to function as oncogenes or tumor suppressors are currently not well understood. However,
these are likely to be linked to their complex functions in cell proliferation, protein degradation,
transcriptional regulation, and canonical signaling pathway modulation and might also be cell
context dependent, impacting the cellular fate of both normal and tumor cells. Indeed, these
signaling pathways, and the TRIB pseudokinases and protein–protein interactions that regulate
them, present new and potentially important pharmacological opportunities for therapeutic
intervention [91,92] in both metabolic and proliferative disorders.
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